LH
Labcorp
$254.43
▼ 0.5%Updated Today 7:15 PM ET
▼ Down 2.1% over the last 12 months
Market Cap
$20.98B
P/E
22.33x
Forward P/E (est.)
17.15x
ROE
10.9%
Revenue Growth
7.3%
EPS Growth
30.2%
Profit Margin
6.7%
FCF Yield
5.2%
Debt / Equity
0.66x
ROIC
7.0%
Interest Coverage
6.18x
Current Ratio
1.73x
Dividend Yield
1.1%
Implied Growth (rev. DCF)
3.1%
Rating Score
58/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what LH's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. LH trades near $254.43, below its 50-day average ($261.54) and 200-day average ($267.57). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 46 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. LH's is $5.87 (~2.3% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month LH found buyers near $250.58 (support) and sellers near $275.00 (resistance); its 52-week range is $241.81–$293.72. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.0× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Labcorp (LH) is a large-cap company in the Health Care Services industry, part of the Health Care sector of the S&P 500, with a market value around $20.98B.
In its latest reported year it generated about $13.95B in revenue and $876.50M in net profit.
Our model rates LH Favorable (58/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
1.5%
Revenue moved from $13.14B in 2021 to $13.95B in 2025, a 1.5% compound annual growth rate. The most recent year grew a steady 7.3% year over year. Slower, mature growth is common for established businesses.
Gross Margin
28.8%
Operating Margin
9.9%
Net Margin
6.3%
ROE
10.9%
Labcorp keeps about 6.7% of each sales dollar as net profit, with a 28.8% gross margin and 9.9% operating margin. Return on equity is 10.9% and return on invested capital about 7.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$6.21B
Net Debt
$5.22B
Net Debt / EBITDA
3.77x
Debt / Equity
0.66x
Leverage: debt-to-equity is 0.7x, and operating profit covers interest about 6.2x, with a current ratio of 1.7x. That is a moderate, manageable debt load for most businesses. It carries roughly $6.21B of total debt against $981.10M of cash.
Operating CF
$1.64B
Free Cash Flow
$1.21B
FCF Margin
8.6%
In the latest year Labcorp produced about $1.64B of operating cash flow and $1.21B of free cash flow after capital spending. That is a free-cash-flow yield of about 5.2% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
22.33x
P/S
1.56x
P/B
2.33x
EV / EBITDA
13.04x
LH trades at 22.3x trailing earnings (about 17.2x on estimated forward earnings), 1.6x sales, and 2.3x book value. Reverse-engineering today's price implies the market expects roughly 3.1% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How LH stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), LH ranks #22 of 59 by our overall rating. It trades at roughly in line versus the sector on earnings (22.3x P/E vs. 25.4x median) with a lower return on equity (10.9% vs. 14.9%) and slower revenue growth (7.3% vs. 7.9%).
P/E vs sector
22.3x
median 25.4x
ROE vs sector
10.9%
median 14.9%
Growth vs sector
7.3%
median 7.9%
Sector rank
#22
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$186.13 – $315.00
vs. $254.43 today · expected CAGR -6% – 4%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $14.93B | $15.97B | $17.09B | $18.29B | $19.57B |
| Net income | $895.70M | $958.40M | $1.03B | $1.10B | $1.17B |
| EPS | $10.92 | $11.69 | $12.51 | $13.38 | $14.32 |
| Share price (low) | $142.00 | $151.94 | $162.58 | $173.96 | $186.13 |
| Share price (high) | $240.31 | $257.13 | $275.13 | $294.39 | $315.00 |
| CAGR (low–high) | -44% / -6% | -23% / 1% | -14% / 3% | -9% / 4% | -6% / 4% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for LH:
- Healthy free-cash-flow yield (~5.2%) funds buybacks and dividends.
- Our model's overall read is Favorable (58/100).
The case against LH:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Labcorp is a large-cap health care business growing at a mature pace, with modest profitability, and a sound balance sheet. It trades at 22.3x earnings, which our model scores Favorable (58/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.